Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Biogen Inc (NASDAQ: BIIB) closed the day trading at $156.00 up 0.37% from the previous closing price of $155.43. In other words, the price has increased by $0.37 from its previous closing price. On the day, 1.62 million shares were traded. BIIB stock price reached its highest trading level at $156.18 during the session, while it also had its lowest trading level at $153.63.
Ratios:
For a better understanding of BIIB, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.38 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.67. For the most recent quarter (mrq), Quick Ratio is recorded 0.80 and its Current Ratio is at 1.26. In the meantime, Its Debt-to-Equity ratio is 0.41 whereas as Long-Term Debt/Eq ratio is at 0.30.
On November 14, 2024, Citigroup started tracking the stock assigning a Neutral rating and target price of $190.Citigroup initiated its Neutral rating on November 14, 2024, with a $190 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 03 ’24 when Singhal Priya sold 431 shares for $204.22 per share. The transaction valued at 88,019 led to the insider holds 5,316 shares of the business.
Singhal Priya bought 431 shares of BIIB for $88,019 on Sep 03 ’24. On Apr 02 ’24, another insider, Singhal Priya, who serves as the Head of Development of the company, sold 93 shares for $213.09 each. As a result, the insider received 19,817 and left with 4,886 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIIB now has a Market Capitalization of 22732165120 and an Enterprise Value of 27683917824. As of this moment, Biogen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.09, and their Forward P/E ratio for the next fiscal year is 9.31. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.90. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.46 while its Price-to-Book (P/B) ratio in mrq is 1.39. Its current Enterprise Value per Revenue stands at 2.881 whereas that against EBITDA is 9.596.
Stock Price History:
Over the past 52 weeks, BIIB has reached a high of $268.30, while it has fallen to a 52-week low of $155.28. The 50-Day Moving Average of the stock is -14.94%, while the 200-Day Moving Average is calculated to be -25.23%.
Shares Statistics:
Over the past 3-months, BIIB traded about 1.27M shares per day on average, while over the past 10 days, BIIB traded about 1696680 shares per day. A total of 144.90M shares are outstanding, with a floating share count of 144.68M. Insiders hold about 0.71% of the company’s shares, while institutions hold 89.28% stake in the company. Shares short for BIIB as of 1730332800 were 3120565 with a Short Ratio of 2.46, compared to 1727654400 on 2849021. Therefore, it implies a Short% of Shares Outstanding of 3120565 and a Short% of Float of 2.42.
